Pentoxifylline could be a significant aspect of detecting OCP.

Article

The cytokine, pentoxifylline, is a safe and effective way to control tumor necrosis factor?a (TNF-a) in conjunctiva affected by ocular cicatricial pemphigoid (OCP).

The cytokine, pentoxifylline, is a safe and effective way to control tumor necrosis factor–a (TNF-a) in conjunctiva affected by ocular cicatricial pemphigoid (OCP), states an investigation published in the European Journal of Ophthalmology.

Dr Mohamed A. El Darouti et al., Department of Dermatology, Kasr Aini Hospital, University of Cairo, Egypt, performed a randomized, controlled, comparative, blinded study on 30 patients with various grades of OCP. They were split into 2 randomized groups of 15- group A received pulse steroid and cyclophosphamide therapy. Group B were administered both pulse steroid and cyclophosphamide therapy and intravenous pentoxifylline.

An additional 20 patients were included as the control and had their serum TNF-a level compared to the OCP patients. All patients were assessed clinically, histopathologically, and serologically before and after therapy.

Significant improvement was seen in group B in the clinical and histopathologic evalutation. The serum TNF-a levels in OCP patients pre-therapy were higher compared to the control cases.

After therapy group B patients experienced a significant reduction in serum TNF-a compared to those in group A with 77.4±26.1 to 19.2±15.6 and 50.3±14.3 to 36.2±18.3, respectively.

The study demonstrates the efficacy of pentoxifylline to pulse steroid cyclophosphamide therapy is successful in controlling OCP by reducing TNF-a levels.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.